Form 8-K Zentalis Pharmaceuticals For: Sep 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
Oppenheimer Reiterates Outperform Rating on Zentalis Pharmaceuticals (ZNTL)
September 16, 2024 11:55 AM EDTOppenheimer analyst Matt Biegler reiterated an Outperform rating and $20.00 price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL).
The analyst comments "Monday, Zentalis announced resolution of azenosertibs partial clinical hold. We were delighted that the resolution came "no strings attached" i.e., no risk... More
